Step-by-step guidance on conducting prospective meta-analyses

Session: 

Oral session: Innovative solutions to challenges of evidence production (5)

Date: 

Thursday 24 October 2019 - 16:00 to 17:30

Location: 

All authors in correct order:

Seidler AL1, Hunter K1, Cheyne S1, Ghersi D2, Berlin J3, Askie L1
1 NHMRC Clinical Trials Centre, University of Sydney, Australia
2 National Health and Medical Research Council, Australia
3 Johnson & Johnson, USA
Presenting author and contact person

Presenting author:

Anna Lene Seidler

Contact person:

Abstract text
Background: prospective meta-analyses (PMA) can reduce many of the problems associated with traditional (retrospective) meta-analyses by specifying study selection criteria, hypotheses and analyses a priori, before the results of included studies are known. This can reduce the risk of publication bias and selective outcome reporting, and enables researchers to harmonise their ongoing research efforts to answer important questions with greater certainty. However, despite rising numbers of PMA in health research, the terminology and definitions used to date have lacked clarity and consistency, and there is little guidance on how to conduct PMA. This threatens successful implementation and interpretation of PMA.

Objective: to develop step-by-step guidance on how to conduct PMA.

Methods: we, the Cochrane PMA methods group, developed step-by-step guidance based on 1) a scoping review of methodology papers, 2) a scoping review of existing PMA, 3) expert opinions from the PMA group, and 4) experiences with previous PMA. We illustrate each step with a recent case study.

Results: we describe seven steps for conducting a PMA (Figure). First, a protocol needs to be developed, including details on collaboration policies such as core outcomes to be collected by all studies (Step 1). Next, a systematic search for planned/ongoing studies should be conducted, including a search of trials registries, medical databases and contacting stakeholders (Step 2) and eligible studies need to be identified for inclusion (Step 3). Importantly, only studies for which the results are not known can be included in a PMA. These studies are then invited to form a collaboration (Step 4), ideally including a central steering and data analysis committee, and representatives from each study. As a next step, core outcomes and common intervention features are agreed upon within the collaboration, and a statistical analysis plan is agreed (Step 5). This can be particularly useful for rare but important outcomes such as adverse side effects, that individual studies would not have enough power to test statistically. There is usually a waiting period while all studies are being completed, before the evidence is synthesized, and certainty of evidence is assessed by adapting tools such as GRADE (Step 6). Results should be reported using adapted versions of reporting guidelines such as PRISMA (Step 7).

Conclusion: PMA allow for a greatly improved use of data, whilst reducing bias and research waste. With rising trial registration compliance and new technical advances in machine learning, data management and processing, we see new horizons for PMA. This step-by-step guidance by the Cochrane PMA methods group will improve the understanding of PMA in the research community and enable more researchers to conduct successful PMA.

Patient or healthcare consumer involvement: we will invite healthcare consumers to comment on this research project, to increase its accessibility from their perspective.

Attachments: